A Phase 1, Multiple-Dose, Dose-Escalation Trial of PT2385 Tablets, a HIF-2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma

Trial Profile

A Phase 1, Multiple-Dose, Dose-Escalation Trial of PT2385 Tablets, a HIF-2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 20 Dec 2017

At a glance

  • Drugs Cabozantinib (Primary) ; Nivolumab (Primary) ; PT 2385 (Primary)
  • Indications Renal cell carcinoma
  • Focus Adverse reactions; First in man
  • Sponsors Peloton Therapeutics
  • Most Recent Events

    • 20 Dec 2017 Results published in the Peloton Therapeutics Media Release.
    • 20 Dec 2017 According to a Peloton Therapeutics media release, results (n=26) from this trial is published in the Journal of Clinical Oncology (JCO).
    • 19 Dec 2017 Results (n=51) published in the Journal of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top